TSE:HBP Helix BioPharma (HBP) Stock Price, News & Analysis C$1.58 0.00 (0.00%) As of 06/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Helix BioPharma Stock (TSE:HBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Helix BioPharma alerts:Sign Up Key Stats Today's RangeC$1.58▼C$1.5850-Day RangeC$1.50▼C$2.0552-Week RangeC$0.84▼C$5.40VolumeN/AAverage Volume2,531 shsMarket CapitalizationC$120.68 millionP/E RatioN/ADividend Yield1.50%Price TargetN/AConsensus RatingN/A Company Overview Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers. Read More Receive HBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBP Stock News HeadlinesHelix BioPharma Showcases CEACAM6-Targeted ADC Advances at World ADC LondonFebruary 24, 2026 | tipranks.comHelix BioPharma Extends LEUMUNA Option with metaShape in Metabolic Disease PushFebruary 5, 2026 | tipranks.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.June 15 at 1:00 AM | Banyan Hill Publishing (Ad)Helix BioPharma Shareholders Back Board, Auditor and Share Consolidation PlanJanuary 30, 2026 | tipranks.comHelix BioPharma Reports Fiscal 2025 Results and Strategic DevelopmentsOctober 29, 2025 | tipranks.comHelix BioPharma Addresses Unusual Market Activity Amidst Ongoing Cancer Treatment DevelopmentsOctober 6, 2025 | tipranks.comHelix BioPharma to Present at Q3 2025 Investor Summit and Plans NASDAQ UplistingSeptember 9, 2025 | tipranks.comHelix BioPharma Corp.: Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025September 9, 2025 | finanznachrichten.deSee More Headlines HBP Stock Analysis - Frequently Asked Questions How have HBP shares performed this year? Helix BioPharma's stock was trading at C$2.37 at the beginning of the year. Since then, HBP stock has decreased by 33.3% and is now trading at C$1.58. How were Helix BioPharma's earnings last quarter? Helix BioPharma Corp. (TSE:HBP) issued its quarterly earnings data on Friday, June, 12th. The biopharmaceutical company reported ($0.01) EPS for the quarter. How do I buy shares of Helix BioPharma? Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Helix BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU). Company Calendar Last Earnings6/12/2026Today6/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:HBP CIKN/A Webwww.helixbiopharma.com Phone+1-416-9253232FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$50.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.79% Return on Assets-279.98% Debt Debt-to-Equity Ratio2.34 Current Ratio0.04 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.14 per share Price / Cash Flow11.32 Book ValueC$0.20 per share Price / Book7.86Miscellaneous Outstanding Shares76,378,000Free FloatN/AMarket CapC$120.68 million OptionableNot Optionable Beta0.42 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (TSE:HBP) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
